<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180687</url>
  </required_header>
  <id_info>
    <org_study_id>02.CD/218E</org_study_id>
    <secondary_id>Dr. David Peck</secondary_id>
    <secondary_id>Prof. Sir Ara Darzi</secondary_id>
    <nct_id>NCT00180687</nct_id>
  </id_info>
  <brief_title>Clinical Trial of the Use of Intraperitoneal Local Anaesthetic</brief_title>
  <official_title>Prospective Double Blind Randomized Controlled Trial of the Use of Intraperitoneal Nebulised Local Anaesthetic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing keyhole gall bladder removal will be divided into 3 groups, one control,
      one will have local anaesthetic and the third will have normal saline nebulised into their
      abdomen before closure of the wounds to reduce postoperative pain. These medications will be
      given on top of the standard pain management protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain post laparoscopic procedures can be divided into access related, operation site and
      distension related. The access type can be attenuated by the use of sub dermal infiltration
      of local anaesthetic and rarely causes significant discomfort. It has been advocated that
      placement of a peritoneal gas drain significantly reduces postoperative pain particularly
      referred to the shoulder tip. Realistically, however, if attention is paid to expelling the
      residual gas at the end of the procedure this complication is rarely problematic. Operative
      site pain however is more difficult to manage. In limited gynaecological procedures it has
      been shown that local installation of local anaesthetic decreased the analgesic requirement
      of patients post operatively. These observations would not be as transferable to more
      extensive colorectal or solid organ surgery as the amount of local anaesthesia required would
      be toxic to the patient. Use of the nebuliser, however maybe able to alleviate pain by
      efficiently using the dosage required.

      This is a prospective randomised double blind trial. Sixty patients will be allocated
      randomly between three groups, 20 patients in each group:

        1. Control group

        2. Nebulised intraperitoneal local anaesthetic (Bupivacaine 0.25%, 3mg/Kg)

        3. Nebulised intraperitoneal normal saline Ward staff will be blinded to which group the
           patients are in. All patients undergoing laparoscopic cholecystectomy who have given
           written, informed consent are eligible for inclusion. Patients with local anaesthetics
           allergy and patients whom pain evaluation is considered unreliable due to chronic opiate
           use or neurological diseases are excluded.

      No pre-medication is to be given and a standardised anaesthetic technique is to be employed
      for all patients.

      Standard 4 ports technique for laparoscopic cholecystectomy will be used with intraperitoneal
      pressure between 12-14 mmHg. This will be achieved using CO2 as the insufflation gas.

      The local anaesthetic (approximately 10mls) will be delivered via a fine sterile catheter
      that will be inserted via the epigastric port under direct vision at the end of the
      procedure. Afterward the pneumoperitoneum will be deflated and the wound will be closed and
      subcutaneous local anaesthetic will be injected in and around the wounds.

      Postoperatively, all the patients will have PCA as the main analgesia supported by NSAIDs
      unless contraindicated. Patients will eat and drink as desired and drips will be taken as
      soon as it is safe to do so.

      Postoperative pain scoring will be stared in recovery and continue on the wards using the
      visual analogue scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Postoperative Pain</measure>
    <time_frame>0 hours, 6 hours, 12 hours, 24 hours</time_frame>
    <description>Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Vomiting / Nausea Episodes</measure>
    <time_frame>24 hours</time_frame>
    <description>Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hours Needed for Safe Mobilization</measure>
    <time_frame>24 Hours</time_frame>
    <description>Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Morphine Use</measure>
    <time_frame>24 Hoiurs</time_frame>
    <description>The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IP Aerosolized Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulised Bupivacaine intraperitoneally</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injected Bupivacaine intraperitoneally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulised Bupivacaine intraperitoneally</intervention_name>
    <description>Nebulised Marcaine (Bupivacaine)</description>
    <arm_group_label>Nebulised Bupivacaine intraperitoneally</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Nebulised Normal Saline</description>
    <arm_group_label>IP Aerosolized Normal Saline</arm_group_label>
    <other_name>0.9 % Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injected Bupivacaine intraperitoneally</intervention_name>
    <description>Injected Marcaine directly into the peritoneal cavity</description>
    <arm_group_label>Injected Bupivacaine intraperitoneally</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intraperitoneal Therapeutics</intervention_name>
    <description>No Intraperitoneal Therapeutics given</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All they patients undergoing laparoscopic cholecystectomy will be included.

        Exclusion Criteria:

          -  Patients with local anaesthetic allergy, patients on chronic opiate medication or
             those with neurological diseases that make pain evaluation unreliable will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nawar A Alkhamesi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. Epub 2006 Dec 16.</citation>
    <PMID>17180268</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>June 9, 2015</results_first_submitted>
  <results_first_submitted_qc>August 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2015</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College London</investigator_affiliation>
    <investigator_full_name>Nawar Alkhamesi</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Nebulisation</keyword>
  <keyword>Cholecystectomy</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Local Anaesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
        </group>
        <group group_id="P2">
          <title>IP Aerosolized Normal Saline</title>
          <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
        </group>
        <group group_id="P3">
          <title>Nebulised Bupivacaine Intraperitoneally</title>
          <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
        </group>
        <group group_id="P4">
          <title>Injected Bupivacaine Intraperitoneally</title>
          <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
        </group>
        <group group_id="B2">
          <title>IP Aerosolized Normal Saline</title>
          <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
        </group>
        <group group_id="B3">
          <title>Nebulised Bupivacaine Intraperitoneally</title>
          <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
        </group>
        <group group_id="B4">
          <title>Injected Bupivacaine Intraperitoneally</title>
          <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.65" lower_limit="25" upper_limit="75"/>
                    <measurement group_id="B2" value="47.65" lower_limit="26" upper_limit="74"/>
                    <measurement group_id="B3" value="51.60" lower_limit="25" upper_limit="83"/>
                    <measurement group_id="B4" value="48.70" lower_limit="34" upper_limit="79"/>
                    <measurement group_id="B5" value="49" lower_limit="25" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Postoperative Pain</title>
        <description>Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.</description>
        <time_frame>0 hours, 6 hours, 12 hours, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
          </group>
          <group group_id="O2">
            <title>IP Aerosolized Normal Saline</title>
            <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Nebulised Bupivacaine Intraperitoneally</title>
            <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
          </group>
          <group group_id="O4">
            <title>Injected Bupivacaine Intraperitoneally</title>
            <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Postoperative Pain</title>
          <description>Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain in Recovery (0 Hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O3" value="3.3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O4" value="9.3" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at 6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="8.1" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="7.2" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="6.7" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O2" value="6.2" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="5.6" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Vomiting / Nausea Episodes</title>
        <description>Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
          </group>
          <group group_id="O2">
            <title>IP Aerosolized Normal Saline</title>
            <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Nebulised Bupivacaine Intraperitoneally</title>
            <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
          </group>
          <group group_id="O4">
            <title>Injected Bupivacaine Intraperitoneally</title>
            <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Vomiting / Nausea Episodes</title>
          <description>Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.</description>
          <units>Number of vomitting / Nausea episodes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O2" value="7.1" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O4" value="6.8" lower_limit="2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hours Needed for Safe Mobilization</title>
        <description>Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
          </group>
          <group group_id="O2">
            <title>IP Aerosolized Normal Saline</title>
            <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Nebulised Bupivacaine Intraperitoneally</title>
            <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
          </group>
          <group group_id="O4">
            <title>Injected Bupivacaine Intraperitoneally</title>
            <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
          </group>
        </group_list>
        <measure>
          <title>Hours Needed for Safe Mobilization</title>
          <description>Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.</description>
          <units>Hours needed for safe mobilization</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O4" value="6.4" lower_limit="3" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Morphine Use</title>
        <description>The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events</description>
        <time_frame>24 Hoiurs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
          </group>
          <group group_id="O2">
            <title>IP Aerosolized Normal Saline</title>
            <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Nebulised Bupivacaine Intraperitoneally</title>
            <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
          </group>
          <group group_id="O4">
            <title>Injected Bupivacaine Intraperitoneally</title>
            <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Morphine Use</title>
          <description>The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="10" upper_limit="45"/>
                    <measurement group_id="O2" value="26.3" lower_limit="10" upper_limit="50"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="16.7" lower_limit="8" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Hours</time_frame>
      <desc>Nausea and Vomiting</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No intraperitoneal therapeutics (No nebulised Bupivacaine)
No Intraperitoneal Therapeutics: No Intraperitoneal Therapeutics given</description>
        </group>
        <group group_id="E2">
          <title>IP Aerosolized Normal Saline</title>
          <description>Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Normal Saline: Nebulised Normal Saline</description>
        </group>
        <group group_id="E3">
          <title>Nebulised Bupivacaine Intraperitoneally</title>
          <description>Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Nebulised Bupivacaine intraperitoneally: Nebulised Marcaine (Bupivacaine)</description>
        </group>
        <group group_id="E4">
          <title>Injected Bupivacaine Intraperitoneally</title>
          <description>Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Injected Bupivacaine intraperitoneally: Injected Marcaine directly into the peritoneal cavity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Patient Chart</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <description>Number of Nausea / vomiting episodes recorded in patient's chart</description>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nawar Alkhamesi</name_or_title>
      <organization>Imperial College London</organization>
      <phone>442033121110</phone>
      <email>n.alkhamesi@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

